Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2022 - 2025)
Phathom Pharmaceuticals (PHAT) has disclosed Accumulated Expenses for 4 consecutive years, with $89.8 million as the latest value for Q4 2025.
- For Q4 2025, Accumulated Expenses rose 68.75% year-over-year to $89.8 million; the TTM value through Dec 2025 reached $89.8 million, up 68.75%, while the annual FY2025 figure was $89.8 million, 68.75% up from the prior year.
- Accumulated Expenses hit $89.8 million in Q4 2025 for Phathom Pharmaceuticals, up from $1.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $89.8 million in Q4 2025 and bottomed at $481000.0 in Q1 2022.
- Average Accumulated Expenses over 4 years is $14.2 million, with a median of $5.4 million recorded in 2022.
- On a YoY basis, Accumulated Expenses climbed as much as 4545.03% in 2024 and fell as far as 88.69% in 2024.
- Phathom Pharmaceuticals' Accumulated Expenses stood at $854000.0 in 2022, then soared by 34.19% to $1.1 million in 2023, then soared by 4545.03% to $53.2 million in 2024, then surged by 68.75% to $89.8 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods came in at $89.8 million, $1.4 million, and $18.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.